We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Align (ALGN), Sraumann Cease Talks on iTero Distribution (Revised)
Read MoreHide Full Article
Shares of Align Technologies, Inc. (ALGN - Free Report) dipped 1.73% to close at $305.70 on Friday, following the company’s decision to terminate discussion on a possible development and distribution agreement with Straumann Group on iTero intraoral scanner. Going by a latest press release, Straumann Group has decided not to explore a potential scanner alliance with Align, which was discussed in March as a part of a patent settlement agreement.
At that time, Align and Straumann had signed a non-binding letter of intent for a 5-year global development and distribution deal. Under this development, Straumann had to potentially distribute 5,000 iTero Element scanners, which would have been fully integrated into the Straumann/Dental Wings CARES/DWOS workflow. Additionally, the parties considered exploring the possibility of offering the existing iTero users, access to Straumann’s prosthetic and surgical planning workflows.
Needless to say, termination of any discussion related to the planned distribution of iTero scanner is a setback for Align, as the company is currently focusing on expanding its market base for scanners. According to Align, Straumann will pay it an additional $16 million in lieu of the development and distribution agreement.
The Patent Settlement Agreement at a Glance
For investors’ knowledge, for several years, Align was engaged in a complicated, multi-country (the United States, the United Kingdom and Brazil), multi-court patent litigation with ClearCorrect, a Straumann subsidiary. Upon the completion of this patent settlementagreement, all current and pending litigations with Straumann are supposed to get resolved. Per the terms of the deal, Align has obtained $35 million in patent settlement fees from Straumann.
Align’s iTero in Focus
Per a Research And Markets report, the global 3D dental scanner market is projected to see a CAGR of 10.2% in the 2017-2021 period. These latest developments will help Align cash in on the potential opportunities.
To capitalize on this enormous scope, the company is attempting to extend its customer base within this niche. Although the latest dissolution of the Straumann-deal has been considered a downside for Align, with a series of multiple product developments in the recent times, the company is well-aligned with this strategy.
Strengthening its iTero arm, Align recently introduced an iTero Element Foundation intraoral scanner that will offer dentists digital workflow capabilities to address restorative and patient monitoring intraoral scanning needs.
The company also introduced its first intraoral scanner with near-infrared imaging technology — iTero Element 5D Imaging System. The system has been made commercially available across Canada, European Union countries acknowledging the CE mark (excluding Greece), Switzerland, Norway, Australia, New Zealand, Hong Kong and Thailand. However, the iTero Element 5D Imaging System is currently not available across the United States or Latin America.
Align is also gaining traction from the adoption of its iTero platform by dental service organizations or DSO partners.
We are also upbeat about the company’s widened iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States across majority of the European countries including France, Germany, Italy, Spain and the United Kingdom
Share Price Movement
Over the past three months, shares of Align have outperformed its industry. The stock has rallied 20.5% compared with the industry’s 4.1% rise.
Zacks Rank & Other Key Picks
Align currently carries a Zacks Rank #2 (Buy). Some of the other top-ranked stocks in the broader medical space are Cerner Corporation , Penumbra (PEN - Free Report) and Bruker Corporation (BRKR - Free Report) . While Cerner sports a Zacks Rank #1, Penumbra and Bruker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
(We are reissuing this article to correct a mistake. The original article, issued on June 17, 2019, should no longer be relied upon.)
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Align (ALGN), Sraumann Cease Talks on iTero Distribution (Revised)
Shares of Align Technologies, Inc. (ALGN - Free Report) dipped 1.73% to close at $305.70 on Friday, following the company’s decision to terminate discussion on a possible development and distribution agreement with Straumann Group on iTero intraoral scanner. Going by a latest press release, Straumann Group has decided not to explore a potential scanner alliance with Align, which was discussed in March as a part of a patent settlement agreement.
At that time, Align and Straumann had signed a non-binding letter of intent for a 5-year global development and distribution deal. Under this development, Straumann had to potentially distribute 5,000 iTero Element scanners, which would have been fully integrated into the Straumann/Dental Wings CARES/DWOS workflow. Additionally, the parties considered exploring the possibility of offering the existing iTero users, access to Straumann’s prosthetic and surgical planning workflows.
Needless to say, termination of any discussion related to the planned distribution of iTero scanner is a setback for Align, as the company is currently focusing on expanding its market base for scanners. According to Align, Straumann will pay it an additional $16 million in lieu of the development and distribution agreement.
The Patent Settlement Agreement at a Glance
For investors’ knowledge, for several years, Align was engaged in a complicated, multi-country (the United States, the United Kingdom and Brazil), multi-court patent litigation with ClearCorrect, a Straumann subsidiary. Upon the completion of this patent settlementagreement, all current and pending litigations with Straumann are supposed to get resolved. Per the terms of the deal, Align has obtained $35 million in patent settlement fees from Straumann.
Align’s iTero in Focus
Per a Research And Markets report, the global 3D dental scanner market is projected to see a CAGR of 10.2% in the 2017-2021 period. These latest developments will help Align cash in on the potential opportunities.
To capitalize on this enormous scope, the company is attempting to extend its customer base within this niche. Although the latest dissolution of the Straumann-deal has been considered a downside for Align, with a series of multiple product developments in the recent times, the company is well-aligned with this strategy.
Strengthening its iTero arm, Align recently introduced an iTero Element Foundation intraoral scanner that will offer dentists digital workflow capabilities to address restorative and patient monitoring intraoral scanning needs.
The company also introduced its first intraoral scanner with near-infrared imaging technology — iTero Element 5D Imaging System. The system has been made commercially available across Canada, European Union countries acknowledging the CE mark (excluding Greece), Switzerland, Norway, Australia, New Zealand, Hong Kong and Thailand. However, the iTero Element 5D Imaging System is currently not available across the United States or Latin America.
Align is also gaining traction from the adoption of its iTero platform by dental service organizations or DSO partners.
We are also upbeat about the company’s widened iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States across majority of the European countries including France, Germany, Italy, Spain and the United Kingdom
Share Price Movement
Over the past three months, shares of Align have outperformed its industry. The stock has rallied 20.5% compared with the industry’s 4.1% rise.
Zacks Rank & Other Key Picks
Align currently carries a Zacks Rank #2 (Buy). Some of the other top-ranked stocks in the broader medical space are Cerner Corporation , Penumbra (PEN - Free Report) and Bruker Corporation (BRKR - Free Report) . While Cerner sports a Zacks Rank #1, Penumbra and Bruker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
(We are reissuing this article to correct a mistake. The original article, issued on June 17, 2019, should no longer be relied upon.)